Ad Astra Diagnostics has developed innovative diagnostic technologies aimed at providing rapid and accurate blood analysis. One of their key products, QScout® RLD (Rapid Leukocyte Differential), delivers a white blood cell and differential count at the patient’s side in approximately two minutes using just a drop of blood. This system is designed to streamline the testing process by eliminating the need for lengthy machine startup times, sample preparation, and the use of wet reagents. The QScout® RLD is user-friendly, requiring minimal training, and is capable of producing results quickly, making it a valuable tool in urgent medical situations.

In addition to the QScout® RLD, Ad Astra Diagnostics is also working on the next generation of complete blood count (CBC) systems, with a focus on enhancing the early detection of severe infections such as sepsis. The company has been awarded a federal contract to develop this advanced diagnostic system, which aims to provide faster and more reliable test results. The technology employed in these systems utilizes imaging-based methods that leverage artificial intelligence to analyze cells directly, circumventing the limitations associated with traditional flow cytometry and the Coulter Principle. This innovative approach positions Ad Astra Diagnostics at the forefront of rapid diagnostic solutions in the healthcare sector.

United States

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Ad Astra Diagnostics

Company Details